The objective of this study was to determine risk factors for the development of resistance to ␤-lactams/␤-lactamase inhibitors (␤L/␤LIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to ␤L/␤LIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.
T
he incidence of Bacteroides species bacteremia has increased over the past few decades (1) (2) (3) (4) (5) . This increase is likely related to enhanced detection resulting from improved anaerobic culture methods and a more complex at-risk patient population (1) . Anaerobic bacteremia has been associated with recent surgery, malignancy, and immunosuppression (1, (5) (6) (7) (8) .
There are 24 species of Bacteroides in the Bacteroides fragilis group, and they vary considerably in their resistance patterns although rates of resistance to ␤-lactams have increased among most species (2-4, 9, 10). B. fragilis remains the most susceptible while Bacteroides distasonis and Bacteroides thetaiotaomicron have demonstrated higher rates of resistance to ␤-lactams (9) .
The primary objective of this study was to determine the prevalence of and risk factors for Bacteroides species with reduced susceptibility to ␤-lactams/␤-lactamase inhibitors (␤L/␤LIs) and ertapenem in patients with bacteremia.
We performed a retrospective case-control study at a 1,051-bed tertiary care medical center in Baltimore, Maryland. All adult patients hospitalized between 1 January 2007 and 31 August 2013 with blood cultures growing Bacteroides species with ␤-lactam susceptibility testing available were eligible for inclusion. Gram-negative organisms believed to be anaerobes in positive blood culture bottles were subcultured to CDC anaerobic blood agar, laked kanamycinvancomycin (LKV) agar, and Bacteroides bile esculin (BBE) agar and incubated under anaerobic conditions in an anaerobe chamber. Prior to 2012, organisms that grew on these media were further identified as Bacteroides species by the RapID ANA II System (Thermo Fisher Scientific, Waltham, MA, USA). Starting in 2012, organisms were identified via matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using a Bruker microflex instrument, Biotyper software v3.0, and database v3.1.66 (Bruker Daltonics, Billerica, MA).
Antibiotic susceptibility testing was performed via Etest strips (bioMérieux). For the purpose of this study, all isolates with MICs interpreted as intermediate or resistant to amoxicillin-clavulanate, piperacillin-tazobactam, and/or ertapenem according to Clinical and Laboratory Standards Institute (CLSI) recommendations, were classified as resistant (11) . For a majority of isolates, the MIC was not available, so isolates were evaluated based on their susceptibility to the respective antibiotic. Ertapenem is the only carbapenem routinely tested against anaerobes at our institution.
Patients were identified using the TheraDoc clinical surveillance software system. Cases were defined as patients with blood isolates of Bacteroides species resistant to ␤L/␤LIs and/or ertapenem. Patients who had positive blood cultures for Bacteroides species but did not have susceptibility testing performed were excluded. Three controls were matched to each case patient by year of positive culture. A random number generator was used to select controls.
Baseline characteristics of cases and controls were compared using chi-square testing and Fisher's exact test for categorical variables, as appropriate, and the Wilcoxon rank sum test for continuous variables. Variables with a P value of Յ0.20 were entered into a multivariable logistic regression model and automatically selected using a backwards stepwise approach. Data were analyzed using Stata statistical software v12.0 (Stata Corp LP, TX). This study was approved by the Johns Hopkins University School of Medicine Institutional Review Board with a waiver of informed consent.
There were 159 patients with Bacteroides bacteremia identified during the study period. The identified isolates and their corresponding resistance rates are listed in Table 1 . Of these, 26 (16.0%) patients had resistant Bacteroides. Amoxicillin-clavulanate was the most common agent to which isolates were resistant (11.5%), followed by ertapenem (7.0%) and piperacillin-tazobactam (6.8%).
There were five isolates (19%) that were resistant to ertapenem but not ␤L/␤LIs.
There were 101 patients included in the case-control analysis (26 case patients and 75 control patients). Only one suitable control patient was found for one of the case patients. The characteristics of these patients are summarized in (n ϭ 4 [5.3%]), but this difference was not statistically significant (P ϭ 0.12). Since we started routine antibiotic susceptibility testing in 2010, we have not documented metronidazole resistance among Bacteroides species isolates and therefore limited our evaluation to ␤-lactams. Resistance rates in this study were similar to what has previously been reported for amoxicillin-clavulanate but were higher for ertapenem and piperacillin-tazobactam (4, 9). Karlowsky et al. reported that 2.3%, 0.5%, and 12.7% of B. fragilis species were intermediate or resistant to ertapenem, piperacillintazobactam, and amoxicillin-clavulanate, respectively (4). In a report by Snydman et al., the proportions of resistant B. fragilis and B. thetaiotaomicron isolates from 2008 to 2009 to ␤L/␤LIs and ertapenem were Ͻ5% (9). Resistance rates for Bacteroides spp. may vary among other regions, and higher resistance rates have been reported outside North America (12) .
The duration of exposure to ␤L/␤LIs was an important risk factor for resistance in our study. Each additional day of ␤L/␤LI therapy was associated with a 25% increased risk of developing a resistant Bacteroides isolate. Similarly, Nguyen et al. found a significant association between in vitro resistance to ␤-lactams and previous exposure to ␤-lactam antianaerobic agents (e.g., ticarcillin-clavulanate, piperacillin, cefotetan, ampicillin-sulbactam) within the previous 14 days (6). We did not find exposure to metronidazole to be protective against ␤-lactam resistance, as more case patients were exposed to metronidazole than were control patients (19.2% versus 6.7%, respectively).
We found a higher mortality rate in patients with resistant Bacteroides species. This result was likely confounded by more severe underlying disease with a higher percentage of patients with concurrent Gram-negative bacteremia, admissions to the ICU, and longer hospital stays prior to the first positive culture in case patients. In our study, 90% of patients who died received initial appropriate therapy. Only one patient received combination antianaerobic therapy with a ␤L/␤LI and metronidazole. Of the 10 patients with resistant Bacteroides spp. that died, 4 (40%) were treated with ␤L/␤LIs and 4 (40%) were treated with metronidazole. The remaining 2 patients received ertapenem. Because of these small numbers, we are unable to draw any meaningful conclusions about the role of empirical combination antianaerobic therapy.
Resistance patterns vary among regions and institutions; therefore, the single center design limits the generalizability of our findings. We were limited by a small sample size, so we grouped together the ␤L/␤LI agents for analysis. Grouping these agents together makes it difficult to determine if different risk factors for resistance to amoxicillin-clavulanate and piperacillin-tazobactam exist.
Duration of exposure to ␤L/␤LIs is a significant risk factor for the development of resistance to these classes of agents. It is important to use these agents judiciously in an effort to decrease the development of resistance to anaerobic organisms. Routine antimicrobial susceptibility testing and the development of an antibiogram for Bacteroides species can ensure that appropriate empirical therapy is selected.
